- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02565082
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients
Sickle cell disease is a genetic disorder caused by a point mutation on the amino acid sequence of the β chain of hemoglobin.
The most expressive and most frequent complication of the disease is vaso-occlusive crisis, dominated by a painful syndrome. In addition to vaso-occlusive crises, many more chronic biological disturbances are observed in sickle cell patients.Sickle cell disease is considered nowadays as a hypercoagulable state.
However, the approach used so far to the measure of clotting in sickle cell disease was segmented in the sense that the various components of the hemostatic balance were studied separately.The thrombin generation test is a functional test which explores the coagulation globally, integrating both pro players that anticoagulants actors in the system. The investigators already used this test to demonstrate that the hemostatic potential was high in a cohort of affected children compared to control children of the same age.
This test will be used to characterize the hemostatic potential of adult sickle cell patients followed at the CHU Brugmann Hospital.
Study Overview
Status
Conditions
Detailed Description
Sickle cell disease is a genetic disorder caused by a point mutation on the amino acid sequence of the β chain of hemoglobin. This is the most common genetic disease in the world. The majority of patients are in Sub-Saharan Africa; however, the increase in migratory movements of populations helps to move patients out of the initial zones of the disease.
According to recent data, about 400 patients would be followed in the Belgian hospitals, and about 1 in 1500 newborns in Belgium would be a major carrier of hemoglobinopathies. The most expressive and most frequent complication of the disease is vaso-occlusive crisis, dominated by a painful syndrome. In addition to vaso-occlusive crises, many more chronic biological disturbances are observed in sickle cell patients. Their contribution to the course of the disease is becoming increasingly stressing. Among them are intravascular hemolysis, hyper-adhesion of blood cells to vascular endothelium, inflammation, oxidative stress, vasculopathy and bleeding disorders.
Sickle cell disease is considered nowadays as a hypercoagulable state. Indeed, sickle cell patients have a high risk of non-hemorrhagic stroke, thrombosis in the pulmonary arteries and deep vein thrombosis that are otherwise associated with mortality and high morbidity. Many anomalies at various levels in the hemostatic system demonstrate coagulation activation even in clinically stable condition.
However, the approach used so far to the measure of clotting in sickle cell disease was segmented in the sense that the various components of the hemostatic balance were studied separately. This scale is complex, this approach difficult to give a comprehensive and integrated picture of the various disturbances in the system. The thrombin generation test is a functional test which explores the coagulation globally, integrating both pro players that anticoagulants actors in the system. The investigators have used this test to demonstrate that the hemostatic potential was high in a cohort of affected children compared to control children of the same age. In this cohort high hemostatic potential was related to the rate of circulating microparticles and intravascular hemolysis rate. Studies are underway to look for correlations between the hemostatic potential and clinical complications in this pediatric cohort.
The use of thrombin generation test for the study of hemostasis in adult patients with sickle cell disease, and the contribution of coagulation disorders with the occurrence of complications of the disease remain little known. The investigators will therefore:
- Characterize the hemostatic potential of adult sickle cell patients followed at the CHU Brugmann
- Search for links between the hemostatic potential and other biological phenomena observed during the disease (intravascular hemolysis, microparticles, vasculopathy, inflammation)
- Search for correlations with clinical complications
- Evaluate the effect of treatment (including exchange transfusions) on the hemostatic potential.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, 1020
- CHU Brugmann Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Sickle cell disease group: Sickle cell disease patients aged over 18 years
- Healthy volunteers group: Healthy volunteers, age matching with the sickle cell disease group
Exclusion Criteria:
- Sickle cell disease group: Pregnant women, dialysis patients, patients with an hepatic impairment, patients under treatments that can interfere with coagulation
- Healthy volunteers group: Pregnant women, known chronical disease, acute inflammatory syndrome, hemostasis disorder, abnormal complete blood count
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sickle cell disease
This arm will include an approximate number of 50 sickle cell disease patients, homozygous and heterozygous.
|
Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.
Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
|
Other: Control
This arm will include an approximate number of 30 healthy volunteers.
|
Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Coagulation markers
Time Frame: sickle cell patients - stable condition - at upcoming hospital routine follow-up, within maximum two years time
|
The following coagulation markers will be assessed in the blood samples: thrombin and thrombomodulin, protein C, protein S, antithrombin, D-dimer, factor VIII, TFPI (physiological inhibitor of the extrinsic pathway of coagulation).
This will be measured only once for each patient, for this health status.
|
sickle cell patients - stable condition - at upcoming hospital routine follow-up, within maximum two years time
|
Coagulation markers
Time Frame: sickle cell patients - if exsanguinotransfusion needed - immediately prior exsanguinotransfusion, within maximum two years time
|
The following coagulation markers will be assessed in the blood samples:thrombin and thrombomodulin, protein C, protein S, antithrombin, D-dimer, factor VIII, TFPI (physiological inhibitor of the extrinsic pathway of coagulation).
This will be measured only once for each patient, for this health status.
|
sickle cell patients - if exsanguinotransfusion needed - immediately prior exsanguinotransfusion, within maximum two years time
|
Coagulation markers
Time Frame: sickle cell patients - if exsanguinotransfusion needed - immediately after exsanguinotransfusion, within maximum two years time
|
The following coagulation markers will be assessed in the blood samples:thrombin and thrombomodulin, protein C, protein S, antithrombin, D-dimer, factor VIII, TFPI (physiological inhibitor of the extrinsic pathway of coagulation).
This will be measured only once for each patient, for this health status.
|
sickle cell patients - if exsanguinotransfusion needed - immediately after exsanguinotransfusion, within maximum two years time
|
Coagulation markers
Time Frame: sickle cell patients - if vaso-occlusive crisis - during the vaso-occlusive crisis, within maximum two years time
|
The following coagulation markers will be assessed in the blood samples:thrombin and thrombomodulin, protein C, protein S, antithrombin, D-dimer, factor VIII, TFPI (physiological inhibitor of the extrinsic pathway of coagulation).
This will be measured only once for each patient, for this health status.
|
sickle cell patients - if vaso-occlusive crisis - during the vaso-occlusive crisis, within maximum two years time
|
Coagulation markers
Time Frame: healthy volunteers: after informed consent signature, within maximum two years time
|
The following markers will be assessed in the blood samples:thrombin and thrombomodulin, protein C, protein S, antithrombin, D-dimer, factor VIII, TFPI (physiological inhibitor of the extrinsic pathway of coagulation).
This will be measured only once for each volunteer.
|
healthy volunteers: after informed consent signature, within maximum two years time
|
Hemolysis markers
Time Frame: sickle cell patients - stable condition - at upcoming hospital routine follow-up, within maximum two years time
|
Will be measured in the blood samples by the following markers:plasmatic hemoglobin level and the lactate dehydrogenase level.This will be measured only once for each patient, for this health status.
|
sickle cell patients - stable condition - at upcoming hospital routine follow-up, within maximum two years time
|
Hemolysis markers
Time Frame: sickle cell patients - if exsanguinotransfusion needed - immediately prior exsanguinotransfusion, within maximum two years time
|
Will be measured in the blood samples by the following markers:plasmatic hemoglobin level and the lactate dehydrogenase level.This will be measured only once for each patient, for this health status.
|
sickle cell patients - if exsanguinotransfusion needed - immediately prior exsanguinotransfusion, within maximum two years time
|
Hemolysis markers
Time Frame: sickle cell patients - if exsanguinotransfusion needed - immediately after exsanguinotransfusion, within maximum two years time
|
Will be measured in the blood samples by the following markers:plasmatic hemoglobin level and the lactate dehydrogenase level.This will be measured only once for each patient, for this health status.
|
sickle cell patients - if exsanguinotransfusion needed - immediately after exsanguinotransfusion, within maximum two years time
|
Hemolysis markers
Time Frame: sickle cell patients - if vaso-occlusive crisis - during the vaso-occlusive crisis, within maximum two years time
|
Will be measured in the blood samples by the following markers:plasmatic hemoglobin level and the lactate dehydrogenase level.This will be measured only once for each patient, for this health status.
|
sickle cell patients - if vaso-occlusive crisis - during the vaso-occlusive crisis, within maximum two years time
|
Hemolysis markers
Time Frame: healthy volunteers: after informed consent signature, within maximum two years time
|
Will be measured in the blood samples by the following markers:plasmatic hemoglobin level and the lactate dehydrogenase level.This will be measured only once for each volunteer.
|
healthy volunteers: after informed consent signature, within maximum two years time
|
Microparticles level
Time Frame: sickle cell patients - stable condition - at upcoming hospital routine follow-up, within maximum two years time
|
Will be measured in the blood samples both by a capture method (Zymuphen) and FACS.This will be measured only once for each patient, for this health status.
|
sickle cell patients - stable condition - at upcoming hospital routine follow-up, within maximum two years time
|
Microparticles level
Time Frame: sickle cell patients -if exsanguinotransfusion - immediately prior exsanguinotransfusion, within maximum two years time
|
Will be measured in the blood samples both by a capture method (Zymuphen) and FACS.
This will be measured only once for each patient, for this health status.
|
sickle cell patients -if exsanguinotransfusion - immediately prior exsanguinotransfusion, within maximum two years time
|
Microparticles level
Time Frame: sickle cell patients - if exsanguinotransfusion needed - immediately after exsanguinotransfusion, within maximum two years time
|
Will be measured in the blood samples both by a capture method (Zymuphen) and FACS.This will be measured only once for each patient, for this health status.
|
sickle cell patients - if exsanguinotransfusion needed - immediately after exsanguinotransfusion, within maximum two years time
|
Microparticles level
Time Frame: sickle cell patients - if vaso-occlusive crisis - during the vaso-occlusive crisis, within maximum two years time
|
Will be measured both by a capture method (Zymuphen) and FACS.This will be measured only once for each patient, for this health status.
|
sickle cell patients - if vaso-occlusive crisis - during the vaso-occlusive crisis, within maximum two years time
|
Microparticles level
Time Frame: healthy volunteers: after informed consent signature, within maximum two years time
|
Will be measured in the blood samples both by a capture method (Zymuphen) and FACS.
This will be measured only once for each patient, for this health status.
|
healthy volunteers: after informed consent signature, within maximum two years time
|
Inflammatory markers
Time Frame: sickle cell patients - stable condition - at upcoming hospital routine follow-up, within maximum two years time
|
The following markers will be assessed in the blood samples: inflammatory cytokines, TNF, usCRP and interleukines.
This will be measured only once for each patient, for this health status.
|
sickle cell patients - stable condition - at upcoming hospital routine follow-up, within maximum two years time
|
Inflammatory markers
Time Frame: sickle cell patients - if exsanguinotransfusion needed - immediately prior exsanguinotransfusion, within maximum two years time
|
The following markers will be assessed in the blood samples: inflammatory cytokines, TNF, usCRP and interleukines.
This will be measured only once for each patient, for this health status.
|
sickle cell patients - if exsanguinotransfusion needed - immediately prior exsanguinotransfusion, within maximum two years time
|
Inflammatory markers
Time Frame: sickle cell patients - if exsanguinotransfusion needed - immediately after exsanguinotransfusion, within maximum two years time
|
The following markers will be assessed in the blood samples: inflammatory cytokines, TNF, usCRP and interleukines.
This will be measured only once for each patient, for this health status.
|
sickle cell patients - if exsanguinotransfusion needed - immediately after exsanguinotransfusion, within maximum two years time
|
Inflammatory markers
Time Frame: sickle cell patients - if vaso-occlusive crisis - during the vaso-occlusive crisis, within maximum two years time
|
The following markers will be assessed in the blood samples: inflammatory cytokines, TNF, usCRP and interleukines.
This will be measured only once for each patient, for this health status.
|
sickle cell patients - if vaso-occlusive crisis - during the vaso-occlusive crisis, within maximum two years time
|
Inflammatory markers
Time Frame: healthy volunteers - after informed consent signature, within maximum two years time
|
The following markers will be assessed in the blood samples: inflammatory cytokines, TNF, usCRP and interleukines.
This will be measured only once for each volunteer.
|
healthy volunteers - after informed consent signature, within maximum two years time
|
Vascular markers
Time Frame: sickle cell patients - stable condition - at upcoming hospital routine follow-up, within maximum two years time
|
The following markers will be assessed in the blood samples: soluble thrombomodulin, von Willebrand factor, vascular endothelial growth factor, protein C endothelial factor.
This will be measured only once for each patient, for this health status
|
sickle cell patients - stable condition - at upcoming hospital routine follow-up, within maximum two years time
|
Vascular markers
Time Frame: sickle cell patients - if exsanguinotransfusion needed - immediately prior exsanguinotransfusion, within maximum two years time
|
The following markers will be assessed in the blood samples: soluble thrombomodulin, von Willebrand factor, vascular endothelial growth factor, protein C endothelial factor.
This will be measured only once for each patient, for this health status
|
sickle cell patients - if exsanguinotransfusion needed - immediately prior exsanguinotransfusion, within maximum two years time
|
Vascular markers
Time Frame: sickle cell patients - if exsanguinotransfusion needed - immediately after exsanguinotransfusion, within maximum two years time
|
The following markers will be assessed in the blood samples: soluble thrombomodulin, von Willebrand factor, vascular endothelial growth factor, protein C endothelial factor.
This will be measured only once for each patient, for this health status
|
sickle cell patients - if exsanguinotransfusion needed - immediately after exsanguinotransfusion, within maximum two years time
|
Vascular markers
Time Frame: healthy volunteers - after informed consent signature, within maximum two years time
|
The following markers will be assessed in the blood samples: soluble thrombomodulin, von Willebrand factor, vascular endothelial growth factor, protein C endothelial factor.
This will be measured only once for each volunteer.
|
healthy volunteers - after informed consent signature, within maximum two years time
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anne Demulder, MD, CHU Brugmann
- Principal Investigator: Bhavna Mahadeb, St Pierre Hospital
Publications and helpful links
General Publications
- Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010 Dec 11;376(9757):2018-31. doi: 10.1016/S0140-6736(10)61029-X. Epub 2010 Dec 3.
- Le PQ, Ferster A, Cotton F, Vertongen F, Vermylen C, Vanderfaeillie A, Dedeken L, Heijmans C, Ketelslegers O, Dresse MF, Gulbis B. Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management. Med Trop (Mars). 2010 Dec;70(5-6):467-70.
- Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program. 2007:91-6. doi: 10.1182/asheducation-2007.1.91.
- De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. Semin Thromb Hemost. 2011 Apr;37(3):226-36. doi: 10.1055/s-0031-1273087. Epub 2011 Mar 31.
- Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes J Jr, Shah AK, Mankad VN; Investigators of the Cooperative Study of Sickle Cell Disease. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003 Oct;123(2):359-65. doi: 10.1046/j.1365-2141.2003.04594.x.
- Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4-15. doi: 10.1159/000071636.
- Noubouossie DF, Le PQ, Corazza F, Debaugnies F, Rozen L, Ferster A, Demulder A. Thrombin generation reveals high procoagulant potential in the plasma of sickle cell disease children. Am J Hematol. 2012 Feb;87(2):145-9. doi: 10.1002/ajh.22206. Epub 2011 Nov 4.
- Noubouossie DC, Le PQ, Rozen L, Debaugnies F, Ferster A, Demulder A. Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays. Thromb Res. 2012 Aug;130(2):259-64. doi: 10.1016/j.thromres.2011.10.016. Epub 2011 Nov 12.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUB-Drepanocytose-Hemostatic
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingSickle Cell Disease | Sickle Cell SC Disease | Sickle Cell-SS Disease | Sickle Cell RetinopathyNetherlands
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica